Jonathan Grinstein
Verified
Scientist turned storyteller. North American Editor @inside_pm. for story leads: jonathan.grinstein@sagepub.com
Articles by Jonathan Grinstein
AMP 2026: Has the $100 Liquid Biopsy Arrived?
Credit: OsakaWayne Studios / Getty Images / Moment SEATTLE—Fragmentomics. That one word was one of the buzzier terms at the Association for Molecular Pathology (AMP) 2026 Annual Meeting, representing a broader theme of extracting more biological information from increasingly inexpensive sequencing technologies. Traditional liquid biopsies largely focus on detecting mutations or alterations in DNA methylation patterns in cell-free DNA (cfDNA).
AMP 2026: 700,000 Whole Tumor Transcriptomes Reveal Gene Fusion Targets
Credit: BlackJack3D / iStock / Getty Images Plus SEATTLE—In April, Mayo Clinic Laboratories introduced a whole-transcriptome sequencing (WTS) assay that interrogates approximately 20,000 genes, with clinical reporting focused on 1,445—a substantial expansion from its previous 138-gene sarcoma panel. The motivation was straightforward: cancer genomics was advancing faster than targeted diagnostic panels could keep up.
AMP 2026: AI and the Evolving Fundamentals of Molecular Diagnostics
After a strong start at AMP 2026 in Seattle, we’re excited to share insights from some of the meeting’s most compelling presentations and conversations. In our video recap, we explore how Elaine Jaffe, MD, helped transform lymphoma pathology, how Kenneth Aldape, MD, is advancing brain tumor classification through AI and DNA methylation, and how Hanlee Ji, MD, is pushing the boundaries of liquid biopsy with multi-omic profiling.
AMP 2026: Is Human Expertise Limiting AI Diagnostics?
Credit: Pakorn Supajitsoontorn / iStock / Getty Images Plus In 1972, researchers at the University of Leeds published a provocative study in the British Medical Journal. A computer system designed to diagnose acute abdominal pain achieved 91.8% accuracy across 304 patients, compared with 79.6% for the most senior clinician evaluating each case.
AMP 2026: How Elaine Jaffe Rewrote the Rules of Lymphoma Pathology
At the 2026 Association for Molecular Pathology (AMP) meeting in Seattle, Elaine S. Jaffe, MD, NIH Distinguished Investigator and Head of the NCI Hematopathology Section, will receive the Award for Excellence in Molecular Diagnostics, the organization’s highest honor. [Jonathan D. Grinstein] Elaine S. Jaffe, MD, used to keep a “goodie box” of three-by-five index cards documenting peculiar findings under the microscope.
The Plight and Hope of Patients with Hunter Syndrome
Credit: Rasi Bhadramani / iStock / Getty Images Plus In this conversation from the State of Precision Medicine 2026 Summit, Rob Wynn, MD, of the University of Manchester, and Ricky Chu, father of two boys diagnosed with Hunter syndrome (MPS II), take a deep dive into the scientific and human realities of confronting an ultra-rare, progressive inherited disease.
AMP President: AI, Regulation, and Labor Shortages Threaten Molecular Diagnostics
Credit: Mekdet / Getty Images / Moment As molecular diagnostics becomes increasingly sophisticated, the challenge is no longer simply developing new technologies but translating them into reliable, accessible tools for patient care.
Siemens Healthineers' Spin-off Olyrian Diagnostics Targets Lab Modernization
Credit: gorodenkoff / iStock / Getty Images Plus Siemens Healthineers has decided to carve out its in vitro diagnostics (IVD) business under the new name Olyrian Diagnostics as clinical laboratories face a new wave of investment decisions. Aging automation systems, changing testing networks, and growing pressure to demonstrate their value to healthcare organizations are reshaping how laboratories operate and what they expect from diagnostics manufacturers.
Pangenome Finds Thousands of Cancer Mutations Standard Reference Misses
Credit: Tek Image / Getty Images / Science Photo Library A more comprehensive representation of human genetic diversity could significantly improve scientists’ ability to detect cancer-associated mutations, according to a new study in Cell Genomics.
Haplotype-Based ASOs Can Bypass Bespoke Rare Disease Drug Design
Credit: Yuliya Kachan / iStock / Getty Images Plus Antisense oligonucleotides (ASOs) are opening new treatment possibilities for rare genetic diseases, including those caused by mutations too uncommon to attract conventional drug development. But the precision that makes these therapies possible also limits their reach: An ASO designed for one patient’s disease-causing mutation may have little therapeutic value for anyone else.
Ryan Beal: Getting Under Cancer’s Skin
Credit: MirageC / Getty Images / Moment Conventional transdermal delivery has long been limited to a narrow range of molecules, including nicotine, hormones, and certain neurological and psychiatric medications. The challenge is fundamental: Skin evolved to keep foreign substances out, and most drugs lack the physicochemical properties needed to penetrate its protective barriers in therapeutic amounts. Dyve Biosciences is developing a technology that could expand those possibilities.
Single-Nucleus Multi-Omic Profiling Reveals Muscle Genetic Regulation Layer
Credit: xia yuan / Getty Images / Moment For decades, researchers have relied on gene expression to help decipher how genetic variation contributes to disease. However, what if significant genetic effects take place before changes in gene expression can be identified? And, if so, how many potential therapeutic targets have been overlooked as a result?
Circular RNA Shows Clinical Promise in First Published Results from RiboX
Credit: Christoph Burgstedt / iStock / Getty Images Plus A patient was sitting on the couch looking at photos together with his girlfriend when, suddenly, she flinched away from him in disgust. “Stop that! You’re spraying spit everywhere.” For most people, hearing those words from a partner while looking at photos together would be cause for embarrassment, even panic. But for him, it was cause for celebration.
When Sperm Meets Egg, Meet the Robots: UCSF and Conceivable Automate IVF
Credit: SvetaZi / iStock / Getty Images Plus Alan Murray initially set out to develop a simple robotic solution for a single step in in vitro fertilization (IVF). As an engineer, to better understand the mechanics and intricacies of the process, he visited fertility laboratories around the world. There was one major take-home message: there were hundreds of hand-operated steps.
With In Vivo 'Gene Writers,' Tessera Shows DNA Engineering Differentiation
Credit: Anton Vierietin / Creatas Video+ / Getty Images Plus The ability to permanently insert large stretches of DNA into the human genome remains one of the central challenges of genetic medicine. While CRISPR-based technologies have transformed genome editing, gene-length insertion remains difficult, particularly when engineering cells directly inside the body rather than extracting, modifying, and reinfusing them.
Hussam Al Kateb: Inside Mayo Clinic’s Molecular Diagnostic Revolution
Credit: Firstsignal / iStock / Getty Images Plus Mayo Clinic Laboratories processes millions of diagnostic tests annually, receiving patient samples from around the world. That scale presents challenges but also opportunities to develop and validate sophisticated assays across diverse tumor types and specimen conditions, including rare cases smaller laboratories may seldom encounter.
Worlds Apart: Genomics Experts Still Split on Newborn Sequencing Guidelines
Credit: BlackJack3D / iStock / Getty Images Plus BOSTON, October 8, 2026—“How many people have gotten their whole genome sequenced?”Ten hands went up. “How many people would get their whole genome sequenced today?”Twenty hands went up. Then came the inverse question. “How many people would not want their whole genome sequenced, even if it was free?” Thirty hands went down. Fifty hands went up. “How many people would have their newborn’s whole genome sequenced?” Twenty hands went down.
Whole-Genome Diagnostics Evolve with RNA and Pangenome Integration
Credit: TanyaJoy / iStock / Getty Images Plus For a patient with a suspected genetic disorder, a negative sequencing result does not necessarily mean the answer isn’t in their DNA. The disease-causing variant may have been mapped incorrectly, dismissed as benign, or left unclassified. Even whole-genome sequencing (WGS), which captures far more DNA than whole-exome sequencing (WES), can miss a diagnosis.
Reporter’s Notebook: Cell and Gene Therapy’s Success Lies Beyond the Bespoke (Part 2)
Alliance for Regenerative Medicine (ARM) CEO Tim Hunt and CBER director Karim Mikhail highlighted updated frameworks to grow a sustainable cell and gene therapy industry [Credit: Jonathan D. Grinstein] The Cell and Gene Meeting on the Mesa is one of my favorite conferences. This mini–J.P. Morgan Healthcare conference is held in a luxury Phoenix resort where giant fans blow cool mist in outdoor gathering places during scorching temperatures.
Reporter’s Notebook: Cell and Gene Therapy’s Success Lies Beyond the Bespoke (Part 1)
Credit: Eric Mischke / iStock / Getty Images Plus PHOENIX, AZ — In my fifth year attending the Cell and Gene Meeting on the Mesa, I’ve seen a handful of trends trudge forward, stop dead in their tracks, and, in some cases, reverse course. Two years ago, cell and gene therapy (CGT) seemed like an untapped oil reserve waiting to power a new medical era.
Intellia CEO John Leonard on In Vivo CRISPR Gene-Editing Commercial Launch
Credit: Love Employee / iStock / Getty Images Plus Intellia Therapeutics is approaching a defining moment: a potential FDA approval of lonvoguran ziclumeran (lonvo-z; NTLA-2002), a one-time in vivo CRISPR gene-editing therapy intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradykinin levels, for hereditary angioedema (HAE) is expected in March 2027.
Patient-Derived GBM Organoid Platform Probes Radiation and Drug Responses
Credit: DR P. MARAZZI / Getty Images / Science Photo Library A standardized patient-derived glioblastoma (GBM) organoid platform can replicate radiation responses and help identify drugs that could make resistant tumors more treatable. The Cell Reports Medicine study, co-led by Xin Wang, PhD, and MD/PhD student Yusha Sun as well as colleagues from the Perelman School of Medicine at the University of Pennsylvania, used tumor tissue from 48 patients with GBM.
Matt Begemann: The Cancer-Killing CRISPR
Credit: KTSDESIGN / Getty Images / Science Photo Library What began as an effort to improve crops has led to an unexpected potential weapon against cancer. In this episode of Behind the Breakthroughs, Matt Begemann, PhD, senior director of research and development at Confluence Genetics, traces the scientific path from agricultural biotechnology to a novel CRISPR system with applications in oncology, diagnostics, and antimicrobials.
Riaan's Therapeutic Odyssey – Chapter 5: The Family
Riaan at the beach, being carried by his father, Richie Digeorge, in late June 2025. [Gurjot "Jo" Kaur] Eventually, the pieces to create a treatment for Riaan Singh Digeorge came together: the scientists, the disease models, the manufacturing, the regulatory strategy, and the money—the roughly $4 million Jo Kaur and her husband, Richie Digeorge, had helped raise, as Riaan’s program was not powered by pharma but donors.
Oncolytic Virus May Boost First-in-Line Chemotherapy for Metastatic PDAC
Credit: quantic69 / iStock / Getty Images Plus An oncolytic virus may improve the effectiveness of standard first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC), but a Phase IIb trial produced a complicated result: whether it met its primary efficacy endpoint depends on which patients were included in the analysis.
Just a Flesh Wound: The Combative Quest for Cancer's Holy Grail
Credit: Vasil Dimitrov / iStock / Getty Images Plus The Black Knight in Monty Python and the Holy Grail is not easily dissuaded. Even with both arms cut off and lying on the ground before him, he insists there is no cause for concern: It’s “just a flesh wound.” In the dispute over GRAIL’s Galleri multi-cancer early detection (MCED) blood test, it is tempting to cast someone as the Black Knight. Critics point to a large randomized trial that missed its primary endpoint.
Riaan's Therapeutic Odyssey – Chapter 4: The Drug Developers
Riaan Singh Digeorge [Gurjot "Jo" Kaur] Riaan Singh Digeorge received his experimental gene therapy on April 21, 2026, representing the culmination of nearly five years of work by his family, scientists, clinicians, and supporters. For Brandon Henry, MD, PhD, a physician-scientist and rare-disease drug developer, the first administration isn’t the finish line but the point where another difficult phase of drug development begins.
Off Script: Why Some CAR T Patients Develop Enterocolitis—and How to Treat It
Credit: ALIOUI Mohammed Elamine / iStock / Getty Images Plus Several years ago, gastroenterologist and clinical researcher Saurabh Mehandru, MD, and researchers in his lab at the Icahn School of Medicine at Mount Sinai were investigating how the immune system was attacking the intestine in ulcerative colitis (UC) patients.
Wei-Wu He: Craig Venter’s Legacy and the Future of Human Longevity
Credit: MirageC / Getty Images / Moment When Wei-Wu He, PhD, executive chairman of Human Longevity Inc. (HLI), asked the company’s AI platform how long he could expect to live, it gave him an estimate of 85 to 90 years. Unsatisfied, he asked what he would need to change to reach 95. The system identified five parameters, including his metabolic health, that could potentially extend his predicted lifespan. He then asked how much additional time he might gain by improving his blood glucose regulation.
Riaan's Therapeutic Odyssey – Chapter 3: The Clinicians
Zachary Grinspan, MD, pediatric neurologist and clinical lead supervising the gene therapy treatment and subsequent care of Riaan. [Gurjot "Jo" Kaur] On April 21, 2026, on the 3rd floor at the Child Neurology at NewYork-Presbyterian/Weill Cornell Medical Center in Manhattan, Zachary Grinspan, MD, was pacing nervously.
Human Cortical Organoids Expand Across a Cortex-Depleted Mouse Brain
Side view of a xenocortical mouse brain showing nerve fibers extending from the human graft (colored with green and red fluorescent proteins) through the mouse brain (blue). [S. Pasca lab / Stanford University] Over his short career, 44-year-old Sergiu Pașca, MD, has changed how scientists study the developing human nervous system.
OpenAI Foundation Gives $125M to Public Data for AI-Driven Health Program
AI medical technology concepts. 3D render. OpenAI’s restructuring last year created not only a new corporate structure for the company behind ChatGPT but also a potentially enormous new philanthropic force: the OpenAI Foundation. Now the Foundation is putting $125 million behind a bet on what increasingly powerful artificial intelligence will need to accelerate medical discovery: better data.
Riaan’s Therapeutic Odyssey – Chapter 2: The Researchers
Riaan and Ana Rita Batista, PhD. [Gurjot "Jo" Kaur] When Jo Kaur was presented with her baby boy Riaan’s whole-exome sequencing (WES) results in March 2021, which revealed biallelic pathogenic variants in ERCC8 as the genetic cause of Cockayne Syndrome (CS), her diagnostic odyssey came to a close—and a whole new one began.
Palani Kumaresan: Roche Diagnostics Is Ramping Up—Should Illumina Be Worried?
Credit: Anand Purohit / Getty Images / Moment For the past year and a half, Roche Diagnostics has been drumming up interest around AXELIOS, its return to next-generation sequencing. The platform officially launched in late June and came out of the gate with an attention-grabbing result: a new world record for clinical sequencing of an entire human genome. But in NGS, better technology—at least on paper—does not always win.
Riaan’s Therapeutic Odyssey - Chapter 1: The Parents
Please wait, the meeting host will let you in soon. Gurjot “Jo” Kaur stared at her computer, waiting to be admitted into a Zoom telehealth meeting with a geneticist. She was ready to end her year-long search for an answer for her 15-month-old son, Riaan. Any second now, she could finally receive one. The waiting room window disappears as the meeting starts, and a doctor appears on screen. “We now know what’s going on with Riaan,” Jo recalled in speaking with Inside Precision Medicine.
Starch Reality: Gene Therapy Gives GSD1a Patients a Metabolic Safety Net
Credit: Olga Pankova / Getty Images / Moment For 14 years, Meredith “Meri” Gussin has never really slept. At night in their Miami home, her husband stays awake long enough to give their son Jamie his midnight dose of cornstarch. Meri takes the next shift, waking at 4 a.m. to deliver another dose through his feeding tube, followed by another in the morning. The cornstarch isn’t simply nutrition (Box 1).
Cancer Vaccine Immunity Boosted by Oxygen-Generating Cryogel
Credit: Sigrid Gombert / Science Photo Library / Getty Images Two recent clinical readouts highlight both the promise and limitations of therapeutic cancer vaccines. On August 19, Moderna and Merck announced that the Phase III INTerpath-001 trial of intismeran autogene plus pembrolizumab met its endpoints for recurrence-free and distant metastasis-free survival in patients with resected stage IIB-IV melanoma.
Tumor-on-a-Chip Can Shrink Breast Cancer Patient Drug Matching to Four Days
Credit: DouglasOlivares / iStock / Getty Images Plus Choosing the right drug for breast cancer can still involve an uncomfortable amount of trial and error. Current treatment selection relies largely on biomarkers and molecular profiling as directly testing multiple drugs against a patient’s own tumor has generally been too slow for routine clinical use.
Basking Biosciences Advances Reversible Clot-Busting Therapy for Acute Stroke
Credit: nopparit / iStock / Getty Images Plus When a patient arrives at an emergency room with an ischemic stroke, physicians face a difficult tradeoff: dissolve the clot quickly enough to save threatened brain tissue without triggering potentially catastrophic bleeding. Shahid Nimjee, MD, PhD, a vascular and endovascular neurosurgeon, knows what the downside of that equation looks like firsthand.
Ken Greenberg: Can Ultrasound Shatter the Gene Therapy Delivery Bottleneck?
Credit: Cylonphoto / iStock / Getty Images Plus Gene therapy has spent decades trying to build a better delivery vehicle. Recent setbacks underscore why: three patients treated with Sarepta’s AAV-based therapies died from acute liver failure last year, while the FDA just placed RegenxBio’s AAV9 Hunter syndrome program on clinical hold after spinal imaging abnormalities emerged in five participants.
Pancreatic Cancer Daraxonrasib Escape Reveals RAS-Driven Vulnerabilities
Credit: selvanegra / iStock / Getty Images Plus For decades, RAS was oncology’s quintessential “undruggable” target. Drugs such as sotorasib and adagrasib began changing that, before Revolution Medicines pushed further with daraxonrasib, a RAS(ON) inhibitor targeting active mutant and wild-type RAS. The implications are particularly significant in pancreatic cancer, where more than 90% of tumors harbor RAS mutations.
CAR Treg Cell Therapy’s New Target: Parkinson’s Disease
Illustration of the human brain with an atrophic substantia nigra (yellow) inside a midbrain (purple), showing the degeneration that occurs in Parkinson's disease. The nerve cells inside the substantia nigra die or become impaired, losing the ability to produce dopamine, an important hormone which plays a role in movement Two of the most significant advances in modern immunology are converging.
David Thaisrivongs: Goldilocks and the First Oral PCSK9 Inhibitor
Credit: Elena Koroleva / iStock / Getty Images Plus Every so often, a technology quietly (and seemingly suddenly) crosses the line from an intriguing scientific idea into a paradigm capable of changing an entire industry. That’s precisely what’s happening with biocatalysis: the use of natural or engineered biological systems—specifically enzymes or whole living cells—to accelerate and direct chemical transformations.
Clinical Data-Matched Patient Organoids Customize Drug-Resistant TNBC Treatment
Credit: Artur Plawgo / Getty Images / Science Photo Library Patient-derived organoids—tiny three-dimensional replicas of a patient’s tumor that can be grown, genetically profiled, and exposed to hundreds of drugs—have long been touted as the future of precision oncology. Yet despite faithfully recapitulating many genetic and histologic features of the original tumor, they have rarely predicted how patients actually respond to therapy, limiting their use largely to preclinical drug discovery.
Intracranial CD276-Targeted CAR Ts Show Best-in-Class Glioblastoma Potential
Credit: dani3315 / iStock / Getty Images Plus Glioblastoma has been the biggest test and graveyard for emerging cell and genetic therapies. About every major modality has been tested, with compelling biological rationale and occasional dramatic responders, but few have shown durable, reproducible clinical benefit. One thing has become clear: in glioblastoma, delivery method may be as important as the cargo. A Phase I trial suggests repeated intracranial CAR T-cell delivery may be gaining traction.
ALS Cognitive Dysfunction Heterogeneity Pinned to Distinct Cell Networks
Credit: nopparit / Getty Images / E+ Amyotrophic lateral sclerosis (ALS) has long been viewed through the lens of motor neuron degeneration. Yet for nearly half of patients, the disease extends well beyond movement, producing impairments in executive function, language, behavior, and, in some cases, frontotemporal dementia. While ALS’s cognitive symptoms are increasingly recognized clinically, their biological basis has remained poorly understood.
Medicine’s New Frontier Isn’t Sequencing—It’s Sensing in Real Time
Clive Brown is a legend in next-generation sequencing (NGS). As former CTO of Oxford Nanopore Technologies (ONT), he helped drive two decades of innovation that transformed genome sequencing. In 2005, Brown’s team at Solexa sequenced the first viral genome, a milestone preceding the company’s acquisition by Illumina in 2007 for $600 million. He later led nanopore sequencing development at ONT, helping reduce whole-genome sequencing (WGS) turnaround times from years to hours.
Simple Blood Test May Predict Rare but Serious CAR T Neurotoxicity
Multiple myeloma, also known as myeloma, is a type of bone marrow cancer. CAR T-cell therapy has changed how we treat relapsed or refractory multiple myeloma (RRMM), leading to deep and sometimes long-lasting remissions. But one of the field’s most troubling questions has remained unanswered: why do a small subset of patients develop delayed neurological complications that can persist long after cytokine release syndrome and ICANS have resolved?
DMD Cell Therapy Delays Disease Progression in Phase III Trial
Credit: Sinhyu / iStock / Getty Images Plus Cell therapies are growing in variety and effectiveness across many diseases. In the fight against Duchenne muscular dystrophy (DMD), deramiocel has emerged as an effective treatment for DMD in patients in early clinical trials. New data from the HOPE-3 Phase III clinical trial, published in The Lancet, expand the efficacy to include patients with advanced DMD.
ADLM 2026: Petite, Portable, and Promising Point-of-Care
The Anvajo booth at 2026 Annual Meeting & Clinical Lab Expo (ADLM) taking place at the Anaheim Convention Center [Jonathan D. Grinstein] Anaheim, CA — Small diagnostic gadgets. There’s an allure that draws me to miniaturized diagnostic tests. Big, clunky instruments, on the other hand, repel me into a U-turn. Between meetings with pharma titans at the 2026 Annual Meeting & Clinical Lab Expo (ADLM), I weaved and bobbed through the massive exhibitor floor at the Anaheim Convention Center.
Show More
loading
Actions
Get in touch with Jonathan
Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack